ClinicalTrials.gg
Not yet recruitingNCT07771517Updated Aug 20, 2026

Role of Kynurenine Pathway and Its Metabolites in Depressive Disorders, Major Depressive Disorder is Suspected to Have the Greatest Burden by 2030,Kynurenine Pathway is Major Route Through Which the Essential Amino Acid Tryptophan is Metabolised and Activated in Time of Stress and Immune Activation.

An observational study in Major Depressive Disorder (MDD), sponsored by Sohag University. Not yet recruiting. Open to participants aged 18 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by Sohag University · Observational

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
90
Ages
18 Years to 18 Years
Sex
All
01

Study summary

This is a case control study including simple random cases of 90 persons, 45 of them have depressive disorders and the other 45 are healthy individuals,age group between 18-60 years old, cases will be recruited from outpatient psychiatric clinic in sohag university hospital, all cases will be exposed to psychological assessment and also laboratory assessment of kynurenine metabolites by using biokits

02

Conditions studied

  • Major Depressive Disorder (MDD)

Keywords

  • Kynurenine pathway
  • MDD
  • Kynurenine pathway in depressive disorders
  • Depressive disorder
  • Bipolar disorder
  • Role of kynurenine pathway and its Metabolites in depressive disorders
03

In context

Depressive Disorder, Major

3,041 studies on the registry are indexed under Depressive Disorder, Major; 588 are open to participants now.

This study's planned enrollment of 90 is below the median of 131 across 400 observational studies indexed under Depressive Disorder, Major.

Browse Depressive Disorder, Major studies →

Lead sponsor

Sohag University is the lead sponsor of 1,230 studies on the registry; 636 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Patients with age group between 18: 60 years old and all cases are drug free of at least 4 months

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age group 18: 60 years old
  • cases are drug free of at least 4 months

Exclusion criteria

Exclusion Criteria:

  • patients with comorbid other psychiatric disorders( SUD,anxiety)
  • patients with IQ below 90
  • patients with psychotic features
  • patients with postpartum depression
  • patients with chronic medical illness that might affect immune function
  • patients under treatment with immune modulating therapy
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
90 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Psychological assessment of patients with depressive disorders

    All cases will be subjected to psychological assessment by using structured clinical interview for DSM-V to assess major depressive disorder,bipolar and other depressivedisorders, Hamilton depression rating scale HAN-D to assess MDD, Hamilton anxiety inventory HAM-A to assess anxiety disorders, Montreal cognitive assessment to assess cognitive functions, Pittsburg sleep quality index to assess quality of sleep and detailed family history will be obtained to assess possibility of genetic factors in health relatives to patients with depressive disorders.

    Time frame: From the enrollment of all cases till three months later

  2. Detect abnormalities in kynurenine pathway in patients with depressive disorders

    Blood samples will be collected from patients and healthy control cases in microbiology laboratory in Sohag university hospital; by using biokits for kynurenine to measure kynurenine level in nanomolar to low micromolar in liter, Add a tryptophan measure outcome to measure tryptophan level in micromol per liter Add a quinolinic acid measure outcome to measure quinolinic acid level in microgram per milliliter by ELISA

    Time frame: From the time of enrollment till 3 months later

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07771517
Lead sponsor
Sohag University
Responsible party
Samar Abdelsamie Asaad (Assistant Lecturer at Sohag university hospital, Sohag University) — Principal investigator
First posted
Aug 18, 2026
Start date
Mar 14, 2027 (estimated)
Primary completion
Aug 20, 2028 (estimated)
Completion
May 20, 2029 (estimated)
Last update
Aug 20, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion